An Anti–VEGF-B Antibody Fragment Induces Regression of Pre-Existing Blood Vessels in the Rat Cornea by Irani, Yazad et al.
Cornea
An Anti–VEGF-B Antibody Fragment Induces Regression of
Pre-Existing Blood Vessels in the Rat Cornea
Yazad D. Irani,1 Pierre D. Scotney,2 Sonja Klebe,3 Lauren A. Mortimer,1 Andrew D. Nash,2 and
Keryn A. Williams1
1Department of Ophthalmology, Flinders University, Adelaide, South Australia, Australia
2CSL Limited, Parkville, Melbourne, Victoria, Australia
3Anatomical Pathology, Flinders University, Adelaide, South Australia, Australia
Correspondence: Yazad D. Irani,
Department of Ophthalmology at
Flinders University, Flinders Medical
Centre, Bedford Park, SA 5042, Aus-
tralia;
yazad.irani@flinders.edu.au.
Submitted: December 21, 2016
Accepted: May 29, 2017
Citation: Irani YD, Scotney PD, Klebe
S, Mortimer LA, Nash AD, Williams
KA. An anti–VEGF-B antibody frag-
ment induces regression of pre-exist-
ing blood vessels in the rat cornea.
Invest Ophthalmol Vis Sci.
2017;58:3404–3413. DOI:10.1167/
iovs.16-21343
PURPOSE. We tested the ability of an antibody fragment with specificity for vascular
endothelial growth factor-B (VEGF-B) to regress nascent and established corneal blood
vessels in the rat.
METHODS. A single chain variable antibody fragment (scFv) with specificity for VEGF-B was
engineered from the 2H10 hybridoma. Binding to rat, mouse, and human VEGF-B was
confirmed by surface plasmon resonance. Activity of the anti–VEGF-B scFv on developing and
established corneal blood vessels was assessed following unilateral superficial cautery in male
and female outbred Sprague Dawley rats. Groups (untreated, control scFv-treated, or anti–
VEGF-B scFv-treated) comprised 6 to 22 rats. Treatment consisted of 5 lL scFv, 1 mg/mL,
applied topically five times per day for 14 days, or two subconjunctival injections, 50 lg scFv
each, applied 7 days apart, or combined topical and subconjunctival treatment. Corneal vessel
area was quantified on hematoxylin-stained corneal flat-mounts, and groups were compared
using the Mann-Whitney U test, with post hoc Bonferroni correction. Immunohistochemistry
for cleaved caspase-3 was performed.
RESULTS. Topical anti–VEGF-B scFv therapy alone did not regress corneal blood vessels
significantly (P > 0.05). Subconjunctival injection and combined treatment regressed 14-day
established corneal blood vessels (25% reduction in vessel area [P ¼ 0.04] and 37% reduction
in vessel area [P < 0.001], respectively, compared to results in untreated controls). Cleaved
caspase-3 was identified in vascular endothelial cells of anti–VEGF-B scFv-treated corneas. In
scFv-treated rats, corneal endothelial cell function was maintained to 12 weeks after
treatment and a normal blink reflex was present.
CONCLUSIONS. The anti–VEGF-B scFv significantly regressed established but not developing
corneal blood vessels in rats.
Keywords: VEGF-B, antibody fragment, corneal neovascularization, eye drops, subconjunc-
tival injection
Avascularity helps to maintain normal human cornealtransparency and immune privilege.1–3 Infection, chemical
or mechanical insult, and inflammation can disrupt the fine
balance between proangiogenic and antiangiogenic factors and
lead to unregulated growth of new corneal blood vessels.3 The
prevalence of corneal neovascularization, a potentially sight-
threatening condition, is estimated to be 1.4 million people per
year in the United States alone.3 As well as causing visual
impairment, neovascularization is a significant risk factor for
the failure of a subsequent corneal graft.4
Vascular endothelial growth factor-A (VEGF-A) is a major
proangiogenic growth factor that promotes neovascularization in
vitro5 and in vivo,6,7 and promotes survival of newly-formed
vessels.8 Intraocular levels of VEGF-A are elevated in many
pathologic conditions, including corneal neovascularization.9,10
Anti–VEGF-A therapy for corneal neovascularization has shown
some benefit in regressing newly-formed vessels,11–13 but
regression of established vessels has not been observed to our
knowledge.11
VEGF-B has structural similarities to VEGF-A,14 but is not
strongly proangiogenic and does not increase blood vessel
permeability.15,16 Recent evidence suggests a major role of
VEGF-B in trans-endothelial fatty acid transport,17 but it also has
been demonstrated to be a potent survival factor (as distinct
from a growth factor) for vascular endothelial cells, pericytes,
and smooth muscle cells.18 In the eye, VEGF-B deficiency leads
to increased apoptosis of endothelial cells and, therefore,
poorer survival of blood vessels in the posterior segment.18
Furthermore, VEGF-B overexpression augments pathologic
new vessel survival in animal models of choroidal and retinal
neovascularization.19 VEGF-B also acts as a survival factor for
different types of neurons, including cortical neurons in the
brain,20 retinal neurons in the eye,20 and motor neurons in the
spinal cord.21 Taken together, these findings suggest that VEGF-
B might be a potential target for therapy directed at established
blood vessels.
Whole antibody therapeutics designed for use in the
anterior segment of the eye are generally administered by
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intracameral or subconjunctival injection, as they penetrate
the cornea poorly following topical application.22,23 How-
ever, antibody fragments, such as the single chain antibody
fragment (scFv), have been shown to penetrate through the
cornea on topical application.23 We describe the generation
and characterization of an anti–VEGF-B scFv with specificity
for human, mouse, and rat VEGF-B.24 We formulated the
anti–VEGF-B scFv for local delivery to the eye and evaluated
its effect on growing, as well as established, vessels in an
alkali-induced model of corneal neovascularization in the
rat.
METHODS
Engineering of Anti–VEGF-B scFv
Antibody variable heavy (VH) and variable light (VL) chain
genes were amplified from cDNA isolated from an anti–
VEGF-B murine hybridoma, 2H10,24 with custom-designed
primers 2H10VHfor, 2H10VHback, 2H10VLfor and
2H10VLback (GeneWorks, Adelaide, Australia; Supplementa-
ry Table S1), using a previously described protocol.25 The
VH and VL were joined using splice-by-overlap-extension
polymerase chain reaction (PCR) to generate a scFv as
described previously.23 The sequence of the scFv was
confirmed using an ABI BigDye Terminator sequencing kit
on an ABI PRISM Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA). Existing scFvs with activity against
Acanthamoeba,26 anti–VEGF-A,27 and influenza virus coat
protein (CSL Ltd, Parkville, Australia), prepared as described
above, were used as negative controls.
Production and Purification of Anti–VEGF-A and
Anti–VEGF-B scFv
For in vitro use, a well-characterized anti-human VEGF-A scFv27
and the newly-constructed anti–VEGF-B scFv were produced in
Escherichia coli and purified by immobilized metal ion
chromatography as described previously.27 Visualization of
the components of protein solutions containing scFv was
achieved by gel electrophoresis. A 5 lg protein sample was
mixed with 43 loading buffer (BioRad, Hercules, CA, USA) with
100 mM dithiothreitol and incubated at 958C for 2 minutes.
Samples were then loaded into wells of a 4% to 20% BioRad
TGX stain free precast gel in a Criterion gel tank. A voltage of
300 V was applied for 20 minutes and the gel was imaged using
the BioRad gel-Doc EZ imager. For in vivo experiments, the
anti–VEGF-B scFv cDNA sequences were codon-optimized for
eukaryotic expression, transiently expressed in FreeStyle 293
cells (Thermo Fisher Scientific, Waltham, MA, USA) and
purified from conditioned medium by immobilized metal
affinity chromatography followed by preparative size exclusion
chromatography into mouse-tonicity PBS.
Binding of Anti–VEGF-B scFv to Human VEGF-B,
Human and Rat VEGF-A
A direct ELISA was used to detect binding of the anti–VEGF-B
scFv to human VEGF-B and human and rat VEGF-A. ELISA
plates were coated with 1 lg/mL recombinant human VEGF-B
(CSL Ltd), human or rat VEGF-A (ProspecTany, Rehovot,
Israel) overnight at 48C in a humidified box, then blocked
with 5% wt/vol skim milk (Fonterra, North Adelaide,
TABLE. Treatment Regimen to Detect the Antineovascular Activity of the Anti–VEGF-B scFv
Treatment Mode of Delivery
Total
scFv, lg
Immediate – commencing day after cautery
Topical Untreated Monitored only, no treatment 0
Control scFv 5 lL eye drop 1 mg/mL 53 daily from days 1–14 after cautery 350




Untreated Monitored only, no treatment 0
Control scFv 5 lL eye drop 1 mg/mL 53 daily from days 1–14 after cautery þ 10
lL subconjunctival injection 5 mg/mL in 20% pluronic F127 on
days 1 and 8 after cautery
450
Anti–VEGF-B scFv 5 lL eye drop 1 mg/mL 53 daily from days 1–14 after cautery þ 10
lL subconjunctival injection 5 mg/mL in 20% pluronic F127 on
days 1 and 8 after cautery
450
Delayed – commencing 15 days after cautery
Topical Untreated Monitored only, no treatment 0
Control scFv 5 lL eye drop 1 mg/mL 53 daily from days 15–28 after cautery 350
Anti–VEGF-B scFv 5 lL eye drop 1 mg/mL 53 daily from days 15–28 after cautery 350
Subconjunctival injection Untreated Monitored only, no treatment 0
Control scFv 10 lL subconjunctival injection 5 mg/mL in 20% pluronic F127 on
days 15 and 22 after cautery
100
Anti–VEGF-B scFv 10 lL subconjunctival injection 5 mg/mL in 20% pluronic F127 on





Untreated Monitored only, no treatment 0
Control scFv 5 lL eye drop 1 mg/mL 53 daily from days 15–28 after cautery þ 10
lL subconjunctival injection 5 mg/mL in 20% pluronic F127 on
days 15 and 22 after cautery
450
Anti–VEGF-B scFv 5 lL eye drop 1 mg/mL 53 daily from day 15–28 after cautery þ 10
lL subconjunctival injection 5 mg/mL in 20% pluronic F127 on
days 15 and 22 after cautery
450
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Australia) in Dulbecco’s A PBS pH 7.2 for 1.5 hours. ScFv then
was added for 1.5 hours at room temperature. Diluent (0.1%
skim milk in PBS) was added as an additional negative control.
Bound scFv was detected with 1:2000 diluted anti-HIS
antibody (Sigma-Aldrich Corp., St. Louis, MO, USA) and
1:1000 horseradish peroxidase conjugated anti-mouse anti-
body (Millipore, Billerica, MA, USA) for 1.5 hours each at
room temperature. Tetramethylbenzidene (TMB; BD, Franklin
Lakes, NJ, USA) was used as the substrate and absorbance was
measured at 450 nm.
Affinity of 2H10 scFv for Human, Mouse and Rat
VEGF-B
The affinity of the 2H10 scFv for human, mouse, and rat
VEGF-B was assessed by surface plasmon resonance. Species-
specific VEGF-B (human, mouse, or rat; CSL Ltd) was
immobilized separately on a CM5 chip (GE Lifesciences,
Pittsburgh, PA, USA) to approximately100 RU. 2H10 scFv was
injected at 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03125, and 0 nM in
duplicate and random order. Association was monitored for
200 seconds and dissociation was monitored for 300 seconds.
Regeneration was accomplished by two 30-second injections
of 6 M guanidine-HCl. Running buffer was HBS-EP (GE
Lifesciences) with 0.1% wt/vol bovine serum albumin (BSA)
pH 7.3. Analysis temperature was 378C with a flow rate of 100
lL/minute.
Functional Neutralization of Human VEGF-B by
Anti–VEGF-B scFv
Neutralization of the functional effects of VEGF-B by the anti–
VEGF-B scFv was assessed using a VEGFR1/EpoR/BaF3 cell-
based assay as described previously.16,28
Formulation of scFv for In Vivo Experiments
ScFvs were formulated for topical delivery as an eye drop to a
final concentration of 1 mg/mL purified protein in 0.9% NaCl
(Chem-Supply, Adelaide, Australia), 0.5% capric acid (Sigma-
Aldrich Corp.) and 1.5% hypromellose (DOW, Midland, MI,
USA), as described previously.23 ScFvs were formulated for
subconjunctival injection at 5 mg/mL with 20% wt/vol Pluronic
F-127 (Sigma-Aldrich Corp.) in normal saline. Aseptic tech-
niques and endotoxin-low glassware was used to prepare all
scFv for in vivo use. Endotoxin levels were measured by the
Limulus amebocyte lysate assay (Associates of Cape Cod, East
Falmouth, MA, USA) and were below 3 EU/mL.
Rats and Anesthesia
All experiments involving animals adhered to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research and were approved by the institutional Animal
Welfare Committee. Adult (>12 weeks) Sprague-Dawley rats
were allowed unlimited access to water and rat chow, and
were exposed to a 12-hour light–dark cycle. Room temperature
was 248C and ambient humidity was maintained at between
40% and 55%. Approximately equal numbers of male and
female rats were used. Anesthesia was induced by inhaled
isoflurane (Bomac, Auckland, New Zealand) in a glass chamber
and maintained with 2% isoflurane in oxygen, 2 L per minute,
delivered through a nose cone.
Induction of Corneal Neovascularization by Silver
Nitrate Cautery
Topical anesthetic agent (0.5% proxymetacaine eye drops;
Alcon, Fort Worth, TX, USA) was applied to the right eye.
After 2 minutes, the right central cornea was cauterized using
a silver nitrate potassium nitrate applicator (Graham Field,
Atlanta, GA, USA) for 5 seconds. The eye was washed with
sterile ophthalmic balanced salt solution (BSS; Alcon),
chloramphenicol ointment (Aspen Pharma, Sydney, Australia)
was applied, and the eyelid was sutured shut for 24 hours.
Treatment With Anti–VEGF-B scFv
The treatment regimen used to assess the antineovascular
activity of the anti–VEGF-B scFv on nascent and established rat
corneal blood vessels in study rats compared to controls is
described in the Table.
Quantification of Corneal Neovascularization
A flat-mount–based method was used for the quantification of
corneal neovascularization. Rats were injected with 35 units of
heparin (Hospira, Lake Forest, IL, USA) per 100 g body weight
by intraperitoneal injection and killed by an overdose of
inhaled isoflurane after 30 minutes. The thoracic and
abdominal cavities were opened and the inferior vena cava
and descending aorta were clamped close to the heart. An
incision was made in the right auricle and a 21-gauge winged
FIGURE 1. Generation of an anti–VEGF-B scFv gene from the 2H10
hybridoma. The VL (lane 1) and VH (lane 2) regions were amplified
from 2H10 hybridoma cDNA, and assembled into an scFv gene (lane 3)
by splice-by-overlap-extension (SOE) PCR. The expected product sizes
for the VL, VH, and SOE product were 387, 407, and 771 bp,
respectively. The observed bands corresponded to expected product
sizes. A 500 ng sample of the 2 Log ladder size-marker was run in lanes
marked L. All fragment lengths are represented in bp.
Anti–VEGF-B scFv Regresses Rat Corneal Blood Vessels IOVS j July 2017 j Vol. 58 j No. 9 j 3406
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936360/ on 07/12/2017
FIGURE 2. Characterization of the anti–VEGF-B scFv. (A) Purification of the anti–VEGF-B scFv by immobilized metal ion chromatography (IMAC).
Aliquots of the crude bacterial lysate (lane 1), flow-through from the IMAC column (lane 2), purified pooled fractions (lane 3), and purified
dialyzed scFv (lane 4) were separated on a 4% to 20% gradient polyacrylamide gel. After purification, the predominant band was approximately 25
kDa, the expected size of the anti–VEGF-B scFv. Samples of 5 lg protein were loaded in each lane and 5 lL of Precision Plus Protein unstained
standard (BioRad) was run in lane L. (B) The anti–VEGF-B scFv demonstrated strong binding to VEGF-B in a direct ELISA. Neither anti–VEGF-A nor
anti-Acanthamoeba scFvs bound to VEGF-B. The bars represent the mean optical density at 450 nm of three technical replicates. Error bars:
standard deviation. (C) Parameters for anti–VEGF-B scFv binding to human, and rat VEGF-B, measured by surface plasmon resonance. (D) The ability
of the anti–VEGF-B scFv and the parental mAb to neutralize the biological activity of VEGF-B was assessed in a cell-based assay. The anti–VEGF-B
mAb and scFv inhibited VEGF-B–induced proliferation in the cell-based assay in a concentration-dependent manner. (E) The binding of the anti–
VEGF-B scFv to human VEGF-B and human and rat VEGF-A was assayed by ELISA. The scFv bound to VEGF-B but not to human or rat VEGF-A. (F)
Anti–VEGF-B scFv was assayed for binding to human VEGF-B by direct ELISA, then stored at 48C for 20 months before binding was retested. Binding
activity of the scFv was maintained during storage.
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infusion set (Terumo, Tokyo, Japan) was inserted into the
cavity of the left ventricle. The rat was perfused with 50 mL
warm heparinized saline, followed by 50 mL of 1:3 hematox-
ylin:PBS, pH 6.0, containing 0.32 mL/l papavarine HCL
(Hospira), at 120 mm Hg through the winged infusion set.
Both eyes were enucleated and placed in buffered formalin for
15 minutes at room temperature and then placed in PBS. The
cornea was dissected and flat-mounted. Flat-mounted corneas
were imaged and the corneal neovascular area was quantified
in a blinded fashion using ImageJ software (National Institutes
of Health [NIH], Bethesda, MD, USA) as described in
Supplementary Figure S1.
Assessment of Corneal Nerve Function
The blink reflex was used as a surrogate for corneal nerve
function. The effect of anti–VEGF-B scFv and the control scFv
on corneal nerve function was assessed using a 6-0 nylon
suture (Ethicon, Somerville, NJ, USA) as described previously.29
The blink reflex was tested in additional groups of animals (4–
18 rats/group) that underwent treatment as described above,
after which they were monitored for an additional 12 weeks, to
assess long-term function.
Endpoint Histology and Immunohistochemistry
for Cleaved Caspase-3
Whole eyes were removed from rats at the end of treatment,
formalin fixed, embedded in paraffin wax, sectioned, and
stained with hematoxylin and eosin as described previous-
ly.30 All sections were examined by a qualified pathologist
(SK).
Apoptotic cells were detected by immunohistochemistry
for cleaved caspase-3 according to the manufacturer’s
instructions (Rabbit anti-cleaved caspase-3 polyclonal
#9661; Cell Signaling Technology, Danvers, MA, USA).
Antibody was diluted to 1/5000 and positive labeling was
detected using the Novolink polymer detection system
(Leica, Wetzlar, Germany) according to the manufacturer’s
instructions. Normal rabbit serum diluted 1/10 in PBS was
used as a negative control. Rat thymus was used as a control
tissue.
Statistical Analysis
Statistical analysis was performed using SPSS 22 software (IBM,
Armonk, NY, USA). As data were not normally distributed
(Shapiro-Wilk test), nonparametric tests were used to deter-
mine statistical significance. Two groups were compared using
the Mann-Whitney U test; three or more groups were
compared using the Kruskal-Wallis test. Comparisons among
subsets of data were performed with the Mann-Whitney U test
with post hoc Bonferroni correction for multiple comparisons.
The significance level (a) was set at 0.05.
FIGURE 3. Effect of topical anti–VEGF-B scFv on 14-day established
corneal neovascularization in the rat. There was no significant
difference in the percentage of the cornea covered by blood vessels
in untreated, control scFv–treated, and anti–VEGF-B scFv-treated
animals (P ¼ 0.87, Kruskal-Wallis test), after topical scFv treatment of
established corneal blood vessels. The box outlines the middle two
quartiles, the line is the median, and the whiskers delineate the
minimum and maximum values, the empty circle represents an outlier.
n ¼ number of rats in each group. Representative corneal flat-mounts
are displayed under each group.
FIGURE 4. Effect of subconjunctival anti–VEGF-B scFv on 14-day
established corneal neovascularization in the rat. Treatment of
established corneal vessels with anti–VEGF-B scFv, delivered by
subconjunctival injection, resulted in significantly less percentage of
the cornea covered by vessels when compared to results in untreated
(*P ¼ 0.04) or control scFv (§P ¼ 0.009)–treated animals (Mann-
Whitney U test). There was no significant difference between
untreated and control scFv–treated groups (#P ¼ 0.73). The box
outlines the middle two quartiles, the line is the median, and the
whiskers delineate the minimum and maximum values. n¼ number of
rats in each group. Representative corneal flat-mounts are displayed
under each group.
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RESULTS
Generation and Characterization of an Anti–VEGF-
B scFv
Products amplified from 2H10 hybridoma cDNA corresponded
to the expected sizes of the VL and the VH genes (387 and 407
base pairs [bp], respectively, Fig. 1). A scFv gene then was
generated using an assembly PCR protocol. The expected size
of the product was 771 bp, and the predominant band
obtained ran slightly below the 800 bp marker (Fig. 1). The
sequence of the scFv gene was confirmed by Sanger
sequencing to match the sequence of the 2H10 hybridoma
VL and VH chain genes (Supplementary Fig. S2). The scFv gene
then was expressed in bacteria, and scFv protein purified for
further characterization.
Purified scFv consisted predominantly of a single species of
approximately 25 kDa when separated on a polyacrylamide gel
(Fig. 2A). Binding of the anti–VEGF-B scFv to human VEGF-B
was assayed by direct ELISA. A strong positive signal was
obtained with the anti–VEGF-B scFv (Fig. 2B; Supplementary
Fig. S3), indicating binding to human VEGF-B. Control scFvs
with specificity for human VEGF-A27 and Acanthamoeba26
returned negligible readings. The anti–VEGF-B scFv bound to
human, mouse, and rat VEGF-B with high affinity (Fig. 2C) and
the data fitted well to a 1:1 kinetics model (Supplementary Fig.
S4). The binding affinity of the anti–VEGF-B scFv to VEGF-B
was highest for human and approximately 3- and 4-fold lower
for the mouse and rat VEGF-B, respectively. The anti–VEGF-B
scFv blocked VEGF-B–induced proliferation of VEGFR1/EpoR/
BaF3 cells, which were engineered to proliferate in the
presence of VEGF-B, with comparable potency to the parental
2H10 monoclonal antibody (mAb; Fig. 2D). However, the anti–
VEGF-B scFv did not bind to human or rat VEGF-A (Fig. 2E).
The anti–VEGF-B scFv maintained binding to human VEGF-B
after storage at 48C for up to 20 months (Fig. 2F). Following
formulation for ocular delivery, the scFv maintained binding to
human VEGF-B, immediately and after 3 months of storage at
48C (Supplementary Fig. S5).
Effects of Anti–VEGF-B scFv Treatment on Corneal
Vessels
Unilateral corneal neovascularization was induced in Sprague-
Dawley rats by superficial cautery with silver nitrate. Neo-
vessels sprouted from the limbal plexus 3 to 4 days after
cautery and reached the site of cautery within 7 to 10 days. At
14 to 28 days after cautery remodeling of the vessels continued
(Supplementary Fig. S6).
The effect of topical treatment with anti–VEGF-B scFv eye
drops, or subconjunctival injection of anti–VEGF-B scFv, or
topical treatment combined with subconjunctival injection on
developing as well as established corneal vessels was assessed
by image analysis on corneal flat-mounts, following euthanasia
of the rats. Anti–VEGF-B scFv, irrespective of treatment
regimen, had no effect on growing vessels (Supplementary
Fig. S7). Furthermore, topical anti–VEGF-B scFv treatment did
not cause regression of established vessels (Fig. 3, P ¼ 0.87).
However, subconjunctival injection of anti–VEGF-B scFv
resulted in a 26% reduction in established corneal vessel area
when compared to results in untreated controls (Fig. 4, P ¼
0.04). Combined topical and subconjunctival injection reduced
corneal blood vessel area by 37% when compared to that in the
untreated group (Fig. 5, P < 0.001). There were no significant
differences between untreated and control scFv-treated groups
(P ¼ 0.66).
The data for combined scFv therapy were separated by sex
(male and female rats) and reanalyzed. Male rats treated with
anti–VEGF-B scFv showed significantly less corneal area
covered with vessels than did untreated or control scFv-treated
males, P ¼ 0.003 and P ¼ 0.009, respectively. There was no
significant difference between untreated and control scFv-
treated males, P ¼ 0.53. A similar result was observed in the
females. Female rats treated with anti–VEGF-B scFv showed
significantly less corneal area covered with vessels than did
untreated or control scFv-treated females, P ¼ 0.006 and P ¼
0.048, respectively. There was no significant difference
between untreated and control scFv-treated females, P ¼
0.11. These data indicated that the anti–VEGF-B scFv regressed
pre-existing corneal blood vessels in male and female rats.
Immunohistochemistry for cleaved caspase-3 was per-
formed to detect apoptotic cells in the corneas of rats treated
with anti–VEGF-B scFv. Blood vessel endothelial cells in the
cornea of anti–VEGF-B scFv-treated rats labeled positive for
cleaved caspase-3 (Fig. 6). Corneal blood vessels in control
scFv-treated rats were negative for cleaved caspase-3. These
data suggested that anti–VEGF-B scFv induced apoptosis in
corneal blood vessels.
Assessment of Side Effects of Treatment
Mild corneal edema was observed after cautery, but resolved
spontaneously. Administration of a scFv formulated in eye drop
form or as a subconjunctival injection was well tolerated, with
no overt signs of inflammation apparent (Supplementary Fig.
S6). The cornea remained clear after administration of scFv
(topical and/or subconjunctival injection) for up to 14 days,
FIGURE 5. Effect of combined topical and subconjunctival anti–VEGF-
B scFv on 14-day established corneal neovascularization in the rat.
Combined topical and subconjunctival scFv caused significant reduc-
tion corneal blood vessel area in anti–VEGF-B scFv-treated animals
when compared to results in either untreated or control scFv-treated
groups (*P < 0.001, Mann-Whitney U test). There was no significant
difference between untreated and control scFv-treated animals, #P ¼
0.66. The box outlines the middle two quartiles, the line is the median,
and the whiskers delineate the minimum and maximum values, the
empty circle represents an outlier. n ¼ number of rats in each group.
Representative corneal flat-mounts are displayed under each group.
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indicating that corneal endothelial cell function was not
adversely affected by the drug treatment or the vehicle.
Assessment of Blink Reflex as a Surrogate for Nerve
Function. A normal blink reflex was observed in animals from
all groups (untreated, control scFv, anti–VEGF-B scFv; Supple-
mentary Table S2). The blink reflex was unaffected up to 12
weeks after cessation of treatment.
Endpoint Histology. Corneas treated with anti–VEGF-B
scFv or control scFv appeared morphologically normal at 12
weeks after cautery (Figs. 7A–C). The corneal epithelium
showed no indication of thinning (Fig. 7D). Furthermore,
treatment with the anti–VEGF-B scFv had no detrimental effect
on the integrity of the corneal endothelial cell monolayer (Fig.
7E).
DISCUSSION
A major therapeutic target for the treatment of corneal
neovascularization is VEGF-A, which stimulates new blood
vessel growth into the cornea.6 A meta-analysis of published
human case studies concluded that subconjunctival and topical
bevacizumab (an anti–VEGF-A antibody) can reduce corneal
neovascular area.31 Further, a randomized controlled trial by
Petsoglou et al.13 demonstrated that subconjunctival injection
of bevacizumab was able to reduce corneal vessel area by 36%
in patients with recent neovascularization, when compared to
results in controls. Thus, anti–VEGF-A therapy is somewhat
effective in treating newly-formed corneal vessels, but treat-
ment of established vessels has hitherto proven more
difficult.32
VEGF-B is closely related to VEGF-A14,33 and, although it
does not induce angiogenesis,15,16 it can act as a potent
survival factor for blood vessels.18,34 VEGF-B–deficient endo-
thelial cells undergo apoptosis in response to oxidative stress
or serum starvation in vitro.18 Moreover, VEGF-B increases
blood vessel density in cardiac ischemia models in the
mouse,35,36 pig, and rabbit.37 These studies indicate that
depletion of VEGF-B is detrimental to blood vessel survival,
while its addition augments blood vessel survival. Furthermore,
VEGF-B has been shown to be expressed endogenously in the
mouse cornea38 and in human aqueous humor,39 and its levels
increased after epithelial debridement.38 Thus, VEGF-B is an
attractive target for the treatment of unwanted, established
blood vessels.
The 2H10 hybridoma produces an antibody with activity
against human, mouse, and rat VEGF-B.24 The cross-species
reactivity of the 2H10 antibody is an attractive property, as it
allows in vivo testing in murine models of disease that can be
translated into human clinical studies with the humanized form
of the antibody.40 The 2H10 antibody has already been shown
to modulate blood vessels at the back of the eye: in a mouse
FIGURE 6. Immunohistochemistry for cleaved caspase-3. Corneal sections from control and anti–VEGF-B scFv-treated rats were labeled with cleaved
caspase-3 antibody to detect apoptotic cells. (A) Rat thymus labeled with normal rabbit serum was used as a negative control. (B) Positive labeling
for cleaved caspase-3 in apoptotic cells in the rat thymus. (C) Blood vessels in the cornea of rats treated with the control scFv were negative for
cleaved caspase-3 (black arrows). Red blood cells in the lumen of blood vessels (blue arrow). (D) Blood vessel endothelial cells labeled positive for
cleaved caspase-3 in corneas treated with anti–VEGF-B scFv (black arrow). Rare corneal epithelial cell labeling positive for cleaved caspase-3 served
as an internal positive control (blue arrow) Scale bars: 20 lm.
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model of oxygen-induced retinopathy, intravitreal injection of
the antibody promoted blood vessel regression and reduced
the number of neovascular tufts.18 This effect likely resulted
from increased endothelial cell apoptosis, as evidenced by
colocalization of TUNELþ cells with isolectin IB4-stained
endothelial cells.18 These data suggested that the 2H10
antibody or a smaller fragment, such as the scFv, might be
useful for the treatment of established corneal vessels.
Antibody fragments, such as scFv’s, are particularly attractive
as they lack the Fc portion of whole antibodies, which has
been shown to be responsible, in part, for off-target effects of
antibody biologics.41
The anti–VEGF-B scFv we constructed maintained the
binding specificity of the 2H10 antibody to VEGF-B, and was
functionally active in vitro and demonstrated high affinity
binding to human, mouse, and rat VEGF-B, and was stable on
storage. Topical or local application is the preferred option for
the delivery of ophthalmic drugs, to reduce the likelihood of
systemic side effects. Subconjunctival injection is an estab-
lished route for administration of drugs to the anterior segment
FIGURE 7. Endpoint histology was performed at 12 weeks following cessation of therapy, to assess toxicity of the treatment. Hematoxylin and
eosin–stained section of a cornea treated with (A) anti–VEGF-B scFv (B) control scFv or (C) untreated. High magnification images of epithelium (D,
F, H) and endothelium (E, G, I). A morphologically normal epithelium was observed in all groups up to 3 months after therapy. Furthermore, a
monolayer of corneal endothelial cells was present. Scale bars: (A–C) 50 lm, (D–I) 10 lm.
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of the eye, and has been used to deliver anti-inflammatory
agents, such as triamcinolone,42 and antibiotics.43 Clinically,
bevacizumab and ranibizumab already have been delivered by
subconjunctival injection for the treatment of nascent corneal
neovascularization.13,32,44
The local administration of anti–VEGF-B scFv did not
prevent the ingrowth of new vessels in a rat model of corneal
neovascularization, when compared to administration in either
untreated or control scFv-treated groups. This result was not
entirely surprising, as transgenic overexpression of VEGF-B
induces neither angiogenesis nor lymphangiogenesis.15,16,45
Furthermore, VEGF-B protein does not induce endothelial cell
proliferation or migration in vitro,46 nor angiogenesis in vivo in
the brain21 or eye.20
Thus, we examined local delivery of anti–VEGF-B scFv for
the treatment of established corneal vessels in the rat. Topical
therapy alone did not lead to regression of corneal vessels.
However, anti–VEGF-B scFv delivered by subconjunctival
injection reduced blood vessels by 25% when compared to
results in a control scFv group. Furthermore, combined
treatment with anti–VEGF-B scFv eye drops and subconjunc-
tival injection proved more effective than subconjunctival
injection alone. Complete regression of the blood vessels was
not observed at the concentration of scFv and time-point
tested. However, a reduction of 37% was achieved compared to
results in controls, which was comparable with the results
observed in a randomized trial of bevacizumab in newly-
developing corneal neovascularization in humans.13 Further-
more, we demonstrated positive labeling for cleaved caspase-3
in the corneal blood vessels of anti–VEGF-B scFv-treated
animals, suggesting that the anti–VEGF-B scFv induced
apoptosis in endothelial cells. Previous studies using the
parental 2H10 antibody, from which the anti–VEGF-B scFv
was derived, observed a similar mechanism of action in an
oxygen-induced retinopathy model in the mouse.18
No adverse side effects associated with the anti–VEGF-B
scFv therapy were observed. However, as VEGF-B is a survival
factor for multiple cell types, including neurons, further
assessment of corneal nerves and the long-term effects on
corneal endothelium must be performed to address safety,
ahead of any clinical trial.
Acknowledgments
The authors thank Miriam Keane for statistical advice, Madison
Helm and Kirsty Kirk for expert animal husbandry, and Michelle
Styles for histology.
Disclosure: Y.D. Irani, None; P.D. Scotney, CSL Ltd (E), P; S.
Klebe, None; L.A. Mortimer, None; A.D. Nash, Research
Australia (S), CSL Ltd (E), P; K.A. Williams, CSL Ltd (F), P
References
1. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal
lymphangiogenesis: evidence, mechanisms, and implications
for corneal transplant immunology. Cornea. 2003;22:273–
281.
2. Niederkorn JY. Immune privilege and immune regulation in
the eye. Adv Immunol. 1990;48:191–226.
3. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an
epidemiologic review. Surv Ophthalmol. 1998;43:245–269.
4. Coster DJ, Williams KA. The impact of corneal allograft
rejection on the long-term outcome of corneal transplanta-
tion. Am J Ophthalmol. 2005;140:1112–1122.
5. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth
factor, platelet-derived growth factor, and insulin-like growth
factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol.
1994;145:1023–1029.
6. Phillips GD, Stone AM, Jones BD, Schultz JC, Whitehead RA,
Knighton DR. Vascular endothelial growth factor
(rhVEGF165) stimulates direct angiogenesis in the rabbit
cornea. In Vivo. 1994;8:961–965.
7. Mesri EA, Federoff HJ, Brownlee M. Expression of vascular
endothelial growth factor from a defective herpes simplex
virus type 1 amplicon vector induces angiogenesis in mice.
Circ Res. 1995;76:161–167.
8. Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E. Vascular
endothelial growth factor acts as a survival factor for newly
formed retinal vessels and has implications for retinopathy of
prematurity. Nat Med. 1995;10:1024–1028.
9. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP.
Requirement for vascular endothelial growth factor in wound-
and inflammation-related corneal neovascularization. Invest
Ophthalmol Vis Sci. 1998;39:18–22.
10. Philipp W, Speicher L, Humpel C. Expression of vascular
endothelial growth factor and its receptors in inflamed and
vascularized human corneas. Invest Ophthalmol Vis Sci.
2000;41:2514–2522.
11. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical
bevacizumab in the treatment of corneal neovascularization:
results of a prospective, open-label, noncomparative study.
Arch Ophthalmol. 2009;127:381–389.
12. Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C.
Short- and long-term safety profile and efficacy of topical
bevacizumab (Avastin) eye drops against corneal neovascu-
larization. Graefes Arch Clin Exp Ophthalmol. 2009;247:
1375–1382.
13. Petsoglou C, Balaggan KS, Dart JK, et al. Subconjunctival
bevacizumab induces regression of corneal neovascularisa-
tion: a pilot randomised placebo-controlled double-masked
trial. Br J Ophthalmol. 2013;97:28–32.
14. Olofsson B, Pajusola K, Kaipainen A, et al. Vascular
endothelial growth factor B, a novel growth factor for
endothelial cells. Proc Natl Acad Sci U S A. 1996;93:2576–
2581.
15. Karpanen T, Bry M, Ollila HM, et al. Overexpression of
vascular endothelial growth factor-B in mouse heart alters
cardiac lipid metabolism and induces myocardial hypertro-
phy. Circ Res. 2008;103:1018–1026.
16. Mould AW, Greco SA, Cahill MM, et al. Transgenic overex-
pression of vascular endothelial growth factor-B isoforms by
endothelial cells potentiates postnatal vessel growth in vivo
and in vitro. Circ Res. 2005;97:e60–e70.
17. Hagberg CE, Mehlem A, Falkevall A, et al. Targeting VEGF-B as
a novel treatment for insulin resistance and type 2 diabetes.
Nature. 2012;490:426–430.
18. Zhang F, Tang Z, Hou X, et al. VEGF-B is dispensable for blood
vessel growth but critical for their survival, and VEGF-B
targeting inhibits pathological angiogenesis. Proc Natl Acad
Sci U S A. 2009;106:6152–6157.
19. Zhong X, Huang H, Shen J, et al. Vascular endothelial growth
factor-B gene transfer exacerbates retinal and choroidal
neovascularization and vasopermeability without promoting
inflammation. Mol Vis. 2011;17:492–507.
20. Li Y, Zhang F, Nagai N, et al. VEGF-B inhibits apoptosis via
VEGFR-1-mediated suppression of the expression of BH3-only
protein genes in mice and rats. J Clin Invest. 2008;118:913–
923.
21. Poesen K, Lambrechts D, Van Damme P, et al. Novel role for
vascular endothelial growth factor (VEGF) receptor-1 and its
ligand VEGF-B in motor neuron degeneration. J Neurosci.
2008;28:10451–10459.
22. Dastjerdi MH, Sadrai Z, Saban DR, Zhang Q, Dana R. Corneal
penetration of topical and subconjunctival bevacizumab.
Invest Ophthalmol Vis Sci. 2011;52:8718–8723.
Anti–VEGF-B scFv Regresses Rat Corneal Blood Vessels IOVS j July 2017 j Vol. 58 j No. 9 j 3412
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936360/ on 07/12/2017
23. Thiel MA, Coster DJ, Standfield SD, et al. Penetration of
engineered antibody fragments into the eye. Clin Exp
Immunol. 2002;128:67–74.
24. Scotney PD, MacKenzie A, Maccarone P, et al. Human vascular
endothelial growth factor B: characterization of recombinant
isoforms and generation of neutralizing monoclonal antibod-
ies. Clin Exp Pharmacol Physiol. 2002;29:1024–1029.
25. Irani Y, Tea M, Tilton RG, Coster DJ, Williams KA, Brereton
HM. PCR amplification of the functional immunoglobulin
heavy chain variable gene from a hybridoma in the presence
of two aberrant transcripts. J Immunol Methods. 2008;336:
246–250.
26. Turner ML, Cockerell EJ, Brereton HM, et al. Antigens of
selected Acanthamoeba species detected with monoclonal
antibodies. Int J Parasitol. 2005;35:981–990.
27. Irani Y, Brereton HM, Tilton RG, Coster DJ, Williams KA.
Production of scFv antibody fragments from a hybridoma with
functional activity against human vascular endothelial growth
factor. Hybridoma (Larchmt). 2009;28:205–209.
28. Makinen T, Jussila L, Veikkola T, et al. Inhibition of
lymphangiogenesis with resulting lymphedema in transgenic
mice expressing soluble VEGF receptor-3. Nat Med. 2001;7:
199–205.
29. Yamaguchi T, Turhan A, Harris DL, et al. Bilateral nerve
alterations in a unilateral experimental neurotrophic keratop-
athy model: a lateral conjunctival approach for trigeminal
axotomy. PLoS One. 2013;8:e70908.
30. Irani YD, Tian Y, Wang M, et al. A novel pressed porous
silicon-polycaprolactone composite as a dual-purpose implant
for the delivery of cells and drugs to the eye. Exp Eye Res.
2015;139:123–131.
31. Papathanassiou M, Theodoropoulou S, Analitis A, Tzonou A,
Theodossiadis PG. Vascular endothelial growth factor inhib-
itors for treatment of corneal neovascularization: A meta-
analysis. Cornea. 2013;32:435–444.
32. Benayoun Y, Adenis JP, Casse G, Forte R, Robert PY. Effects of
subconjunctival bevacizumab on corneal neovascularization:
results of a prospective study. Cornea. 2012;31:937–944.
33. Grimmond S, Lagercrantz J, Drinkwater C, et al. Cloning and
characterization of a novel human gene related to vascular
endothelial growth factor. Genome Res. 1996;6:124–131.
34. Li X, Lee C, Tang Z, et al. VEGF-B: a survival, or an angiogenic
factor? Cell Adh Migr. 2009;3:322–327.
35. Claesson-Welsh L. VEGF-B taken to our hearts: specific effect
of VEGF-B in myocardial ischemia. Arterioscler Thromb Vasc
Biol. 2008;28:1575–1576.
36. Li X, Tjwa M, Van Hove I, et al. Reevaluation of the role of
VEGF-B suggests a restricted role in the revascularization of
the ischemic myocardium. Arterioscler Thromb Vasc Biol.
2008;28:1614–1620.
37. Lahteenvuo JE, Lahteenvuo MT, Kivela A, et al. Vascular
endothelial growth factor-B induces myocardium-specific
angiogenesis and arteriogenesis via vascular endothelial
growth factor receptor-1- and neuropilin receptor-1-depen-
dent mechanisms. Circulation. 2009;119:845–856.
38. Guaiquil VH, Pan Z, Karagianni N, Fukuoka S, Alegre G,
Rosenblatt MI. VEGF-B selectively regenerates injured periph-
eral neurons and restores sensory and trophic functions. Proc
Natl Acad Sci U S A. 2014;111:17272–17277.
39. Chen S, Zhou M, Wang W, et al. Levels of angiogenesis-related
vascular endothelial growth factor family in neovascular
glaucoma eyes. Acta Ophthalmol. 2015;93:e556–e560.
40. Irani Y, Scotney P, Nash A, Williams KA. Species cross-
reactivity of antibodies used to treat ophthalmic conditions.
Invest Ophthalmol Vis Sci. 2016;57:586–591.
41. Bogdanovich S, Kim Y, Mizutani T, et al. Human IgG1
antibodies suppress angiogenesis in a target-independent
manner. Signal Transduct Target Ther. 2016;1:15001.
42. Athanasiadis Y, Tsatsos M, Sharma A, Hossain P. Subconjunc-
tival triamcinolone acetonide in the management of ocular
inflammatory disease. J Ocul Pharmacol Ther. 2013;29:516–
522.
43. Vazirani J, Basu S. Role of topical, subconjunctival, intra-
cameral, and irrigative antibiotics in cataract surgery. Curr
Opin Ophthalmol. 2013;24:60–65.
44. Ahn, YJ, Hwang, HB, Chung, SK. Ranibizumab injection for
corneal neovascularization refractory to bevacizumab treat-
ment. Korean J Ophthalmol. 2014;28:177–180.
45. Rissanen TT, Markkanen JE, Gruchala M, et al. VEGF-D is the
strongest angiogenic and lymphangiogenic effector among
VEGFs delivered into skeletal muscle via adenoviruses. Circ
Res. 2003;92:1098–1106.
46. Sands M, Howell K, Costello CM, McLoughlin P. Placenta
growth factor and vascular endothelial growth factor B
expression in the hypoxic lung. Respir Res. 2011;12:17.
Anti–VEGF-B scFv Regresses Rat Corneal Blood Vessels IOVS j July 2017 j Vol. 58 j No. 9 j 3413
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936360/ on 07/12/2017
